Daily Ards Research Analysis
Two mechanistic studies illuminate endothelial barrier injury pathways in ARDS: chlorolipid 2-chlorohexadecanoic acid covalently modifies RhoA to drive activation, and IL-33 amplifies ER stress and pyroptosis in lung microvascular endothelium. A clinical cohort of older adults hospitalized with RSV shows high pneumonia, coinfection, and mortality rates with worse outcomes linked to chronic lung disease, reinforcing the clinical relevance of endothelial-targeted and anti-inflammatory strategies.
Summary
Two mechanistic studies illuminate endothelial barrier injury pathways in ARDS: chlorolipid 2-chlorohexadecanoic acid covalently modifies RhoA to drive activation, and IL-33 amplifies ER stress and pyroptosis in lung microvascular endothelium. A clinical cohort of older adults hospitalized with RSV shows high pneumonia, coinfection, and mortality rates with worse outcomes linked to chronic lung disease, reinforcing the clinical relevance of endothelial-targeted and anti-inflammatory strategies.
Research Themes
- Endothelial barrier dysfunction mechanisms in ARDS
- Inflammation–ER stress–pyroptosis axis in lung endothelium
- RSV outcomes and bacterial coinfection in older adults
Selected Articles
1. Human lung microvascular endothelial cell protein modification by 2-chlorohexadecanoic acid: RhoA mediates 2-chlorohexadecanoic acid-elicited endothelial activation.
Using clickable 2-ClHA analogs, the authors mapped covalent protein modifications in HLMVECs and identified RhoA as a specific 2-ClHA target and hub. 2-ClHA activated RhoA, impaired barrier function, and increased Ang-2 release; RhoA inhibitors (Rhosin, C3) mitigated these effects, linking MPO-derived chlorolipids to endothelial dysfunction relevant to ARDS.
Impact: This work uncovers a specific chlorolipid–RhoA axis driving endothelial barrier dysfunction, providing mechanistic linkage between neutrophil oxidative products and ARDS pathobiology with actionable targets.
Clinical Implications: Although preclinical, targeting RhoA signaling or chlorolipid formation (e.g., MPO activity modulation) may preserve endothelial integrity in sepsis-associated ARDS; Ang-2 reduction offers a measurable pharmacodynamic marker.
Key Findings
- 2-ClHA covalently modified 11 proteins specifically and 194 proteins in common with HA in HLMVECs.
- RhoA was a specific 2-ClHA-modified protein and network hub; 2-ClHA activated RhoA.
- Rhosin and C3 inhibited 2-ClHA-induced barrier dysfunction and Ang-2 release.
- HA did not induce barrier dysfunction, Ang-2 release, or RhoA activation, confirming pathway specificity.
Methodological Strengths
- Chemical proteomics with clickable lipid analogs and STRING network analysis
- Pharmacologic validation using two independent RhoA inhibitors with functional readouts (barrier function, Ang-2)
Limitations
- In vitro HLMVEC model without in vivo validation
- No direct testing in ARDS patient samples beyond prior associations of 2-ClHA levels
Future Directions: Validate the 2-ClHA–RhoA pathway in vivo and in patient samples; test MPO inhibition or RhoA-targeted therapies for endothelial protection in sepsis/ARDS models.
Chlorolipids are produced during the neutrophil respiratory burst as a result of myeloperoxidase (MPO)-generated hypochlorous acid (HOCl) targeting the vinyl ether bond of plasmalogen phospholipids. The initial products of this reaction are 2-chlorofatty aldehydes (2-ClFALDs), which are subsequently oxidized to 2-chlorofatty acids (2-ClFAs). 2-Chlorohexadecanoic acid (2-ClHA) is the 16-carbon 2-ClFA species, and previous studies have shown that increased levels of plasma 2-ClHA associate with acute respiratory distress syndrome (ARDS)-caused mortality in human sepsis. 2-ClHA causes endothelial barrier dysfunction and increases neutrophil and platelet adherence to the endothelium. In this study, click chemistry analogs of 2-ClHA and hexadecanoic acid (HA) were used to identify proteins covalently modified by 2-ClHA and HA in human lung microvascular endothelial cells (HLMVECs). Eleven proteins were specifically modified by 2-ClHA, and an additional one hundred and ninety-four proteins were modified by both 2-ClHA and HA. STRING analysis of 2-ClHA-modified proteins revealed a network of proteins with RhoA as a hub. RhoA is one of the proteins specifically modified by 2-ClHA and not HA. The RhoA inhibitors, Rhosin and C3, inhibited both 2-ClHA-elicited HLMVEC barrier dysfunction and angiopoietin-2 (Ang-2) release from HLMVEC. Further studies showed 2-ClHA activates HLMVEC RhoA activity. The specificity of the 2-ClHA-RhoA pathway for endothelial activation was further confirmed since HA did not cause HLMVEC barrier dysfunction, Ang-2 release and RhoA activation. Collectively, these studies have identified multiple proteins modified exclusively by 2-ClHA in HLMVECs, including RhoA. These proteomics studies led to the key finding that RhoA is an important mediator of 2-ClHA-caused endothelial barrier dysfunction.
2. IL-33 facilitates endoplasmic reticulum stress and pyroptosis in LPS-stimulated ARDS model in vitro.
In LPS-stimulated hPMVECs, IL-33 heightened ER stress and pyroptosis and disrupted junctional proteins, worsening endothelial permeability. ER stress inhibition (4-PBA) and IL-33 neutralization restored junctional integrity and reduced inflammatory mediators; transcriptomic datasets and ARDS patient serum supported elevated IL-33.
Impact: Links IL-33 to ER stress–pyroptosis in lung endothelium, nominating a cytokine-centric, druggable pathway for ARDS barrier protection.
Clinical Implications: Supports exploration of IL-33 blockade or ER stress modulators as adjunctive therapies to preserve endothelial integrity in ARDS.
Key Findings
- IL-33 expression was elevated in ARDS patient serum and across multiple GEO datasets (GSE237260, GSE216635, GSE89953, GSE263867, GSE5883) and correlated with clinical features.
- In LPS-stimulated hPMVECs, IL-33 enhanced ER stress markers (ATF6, IRE1a, p-ERK) and pyroptosis markers (NLRP3, IL-1β, IL-18) while disrupting junction proteins (Cx43, ZO-1).
- 4-PBA reduced permeability and IL-33 levels and increased connexins; IL-33 neutralizing antibody reversed ER stress/pyroptosis markers and restored junctional proteins.
Methodological Strengths
- Convergent evidence: bioinformatics across multiple GEO datasets and patient serum data
- Mechanistic perturbations using ER stress inhibitor/activator and IL-33 neutralizing antibody with protein-level readouts
Limitations
- In vitro endothelial model without animal validation
- LPS-induced model may not capture full complexity of human ARDS
Future Directions: Test IL-33 blockade in vivo ARDS models and evaluate biomarkers (e.g., IL-33, ER stress markers) in clinical cohorts to support translational development.
BACKGROUND: Inflammatory activation of pulmonary microvascular endothelial cells (PMVECs) initiated by endoplasmic reticulum stress (ERS) contributes to acute respiratory distress syndrome (ARDS). Interleukin 33 (IL-33) has pro-inflammatory and transcriptional regulatory effects. Therefore, this study intends to investigate the effect of IL-33 on ERS and pyroptosis in the hPMVEC. METHODS: The hPMVEC-associated ARDS cell model was induced with lipopolysaccharide (LPS) and treated with 4-PBA (ERS inhibitor), thapsigargin (ERS activator), or IL-33 neutralizing antibody. Western blot and IF staining were performed to analyze the expression of cell-cell junction-associated (Cx37, Cx40, Cx43, Occludin, and Zo-1), ERS-associated (ATF6, IRE1a, and p-Erk), and pyroptosis-associated (NLRP3, IL-1β, and IL-18) proteins. Bioinformatics identified differential expression of IL-33 in ARDS-related datasets and targets of thapsigargin. RESULTS: IL-33 was highly expressed in serum of ARDS patients and in ARDS cohorts from multiple GEO datasets (GSE237260, GSE216635, GSE89953, GSE263867, and GSE5883), and was significantly correlated with clinical features. 4-PBA decreased permeability and IL-33 levels, and increased Cx37, Cx40 and Cx43 levels in the ARDS cell model. IL-33 neutralizing antibody effectively augmented the levels of Cx43 and Zo-1, and diminished the levels of ATF6, IRE1a, p-Erk, NLRP3, IL-1β, IL-18, ROS, and Ca CONCLUSION: IL-33 promotes ERS and pyroptosis, thereby contributing to barrier damage in ARDS cell models. IL-33 is a promising therapeutic target for ARDS.
3. High bacterial coinfection rates and associated mortality among hospitalized older adults with laboratory-confirmed respiratory syncytial virus infection.
In a 12-year single-center cohort of 36 adults ≥50 years with lab-confirmed RSV, pneumonia (72.2%), bacterial coinfection (33.3%), invasive ventilation (41.7%), and hospital mortality (33.3%) were common. Chronic lung disease predicted worse outcomes and 28-day survival; non-survivors more often developed septic shock and ARDS.
Impact: Quantifies severe outcomes and coinfection burden in older adults with RSV and links chronic lung disease to mortality, informing risk stratification and preventive strategies.
Clinical Implications: Older inpatients with RSV, especially with chronic lung disease, warrant early escalation of care, vigilant coinfection assessment, and consideration of preventive measures (vaccination uptake), while balancing antimicrobial stewardship.
Key Findings
- Among 36 older adults with RSV, pneumonia occurred in 72.2%, invasive mechanical ventilation in 41.7%, and hospital mortality was 33.3%.
- Bacterial coinfection rate was 33.3%; pneumonia or coinfection correlated with poorer outcomes.
- Chronic lung disease was more common in non-survivors (66.7% vs. 12.5%, p=0.002) and associated with worse day-28 survival (log-rank p<0.001).
- Non-survivors had higher disease severity, elevated procalcitonin, and more septic shock and ARDS.
Methodological Strengths
- Laboratory-confirmed RSV with clinically relevant outcomes over a 12-year period
- Subgroup analyses including survival (day-28) and comorbidity associations
Limitations
- Small, single-center retrospective cohort limits generalizability
- Potential residual confounding and limited power for multivariable adjustment
Future Directions: Larger multicenter cohorts to define predictors of ARDS and mortality, and interventional studies targeting coinfection prevention in high-risk older adults.
BACKGROUND: Emerging evidence highlights that respiratory syncytial virus (RSV) poses a significant risk to older adults. However, detailed clinical data on elderly patients hospitalized with RSV remains limited. This study investigates the clinical characteristics and outcomes of older adults (aged ≥50 years) hospitalized with RSV infection. METHODS: This retrospective cohort study included hospitalized patients aged ≥50 years with respiratory symptoms and laboratory-confirmed RSV infection at China Medical University Hospital between January 1, 2011, and December 31, 2023. Data on demographic characteristics and clinical presentations were collected. RSV infection-related outcomes were analyzed across various subgroups. RESULTS: This study included 36 patients, with the most prevalent comorbidities being diabetes mellitus (47.2 %), immunocompromised status (36.1 %), and chronic lung disease (30.6 %). Pneumonia was identified in 72.2 % of patients, while 41.7 % required invasive mechanical ventilation, and the hospital mortality rate was 33.3 %. Non-survivors had higher rates of comorbidities, particularly chronic lung disease (66.7 % vs. 12.5 %, p = 0.002), higher disease severity, elevated procalcitonin levels, and were more likely to develop septic shock and acute respiratory distress syndrome. A bacterial coinfection rate of 33.3 % was observed, with patients experiencing pneumonia or bacterial coinfection showing poorer outcomes. Moreover, patients with chronic lung disease exhibited significantly worse day-28 survival (log-rank p < 0.001). CONCLUSIONS: The disease burden of RSV in older adults is amplified by comorbidities such as chronic lung disease, with pneumonia and bacterial coinfections further worsening outcomes. Our findings highlight the need for a more comprehensive understanding and effective preventive strategies to protect this vulnerable population.